Details
Stereochemistry | UNKNOWN |
Molecular Formula | C14H14N4O4 |
Molecular Weight | 302.2854 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NOCC1\N=C\C2=CC=C(C=C2)\C=N\C3CONC3=O
InChI
InChIKey=ODKYYBOHSVLGNU-IAGONARPSA-N
InChI=1S/C14H14N4O4/c19-13-11(7-21-17-13)15-5-9-1-2-10(4-3-9)6-16-12-8-22-18-14(12)20/h1-6,11-12H,7-8H2,(H,17,19)(H,18,20)/b15-5+,16-6+
TERIZIDONE, a structural analog of cycloserine, is a broad spectrum antibiotic used in the treatment of multidrug-resistant tuberculosis. However, its effectiveness is widely debated. Terizidone acts by inhibiting cell wall synthesis by competitively inhibiting two enzymes, L-alanine racemase and D-alanine ligase, thereby impairing peptidoglycan formation necessary for bacterial cell wall synthesis.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2540 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21085831 |
|||
Target ID: CHEMBL2031 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21085831 |
PubMed
Title | Date | PubMed |
---|---|---|
[Results of clinical trials of a new antitubercular agent, terizidone (Terivalidine)]. | 1972 Apr-Jun |
|
Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. | 2013 Oct |
|
Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. | 2018 Jan 1 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C280
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
||
|
WHO-VATC |
QJ04AK03
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
||
|
WHO-ATC |
J04AK03
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID70905098
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
DB12954
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
1707
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
65720
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
TERIZIDONE
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107553
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
57047
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
1199LEX5N8
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
100000077578
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
2602
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
C100142
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
247-186-1
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
SUB15487MIG
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
C90772
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY | |||
|
25683-71-0
Created by
admin on Sat Dec 16 17:04:40 GMT 2023 , Edited by admin on Sat Dec 16 17:04:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY